Testing a new immune therapy for hard-to-treat blood cancer

Plain-English translation of NCT06574568 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is the first human trial of , a new type of medication designed to help your own immune cells fight multiple myeloma cancer. works by connecting your T cells (infection-fighting white blood cells) directly to your myeloma cells, teaching your immune system to attack the cancer. Researchers want to find the right dose and learn how safe and effective this treatment is.

Multiple myeloma often becomes resistant to standard drugs over time, leaving patients with limited options. This medication represents a new approach—using the body's own immune system as a weapon against the cancer—and this trial will show whether it can help people whose myeloma no longer responds to conventional treatment.

Do you qualify?

You likely qualify if…

you have been diagnosed with multiple myeloma that has returned or stopped responding to previous treatments
you have received at least two different classes of prior cancer drugs (such as immunomodulatory drugs, proteasome inhibitors, or anti-CD38 drugs)
you have measurable disease visible on blood tests or urine tests at the time of screening
you are in good enough health to participate, with an expected survival of at least 12 weeks
you have recovered from side effects of previous cancer treatments to mild or no symptoms

You likely don't qualify if…

you have certain rare blood cancers or related conditions like Waldenstrom's Macroglobulinemia or primary light-chain amyloidosis
you have received other BCMA-targeted therapies or CAR-T cell therapies in the past
you have had an organ transplant or stem cell transplant in the last 6 months
you are currently experiencing moderate-to-severe graft-versus-host disease from a previous stem cell transplant
you have received other cancer treatments within the past 2–4 weeks (depending on the type)

What participation looks like

You will receive the study medication as an intravenous injection (through an IV) in 21-day cycles—meaning you'll receive one dose, then wait 3 weeks before the next dose. The trial has two phases: first, researchers will gradually increase doses to find the safest level, and then expand to treat more people at that dose. You'll have regular blood tests, scans, and check-ins to monitor how the treatment is working and watch for side effects.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(12 sites)

China

Beijing Chao-yang Hospital, Capital Medical University, Beijing, Beijing Municipality

Beijing Jishuitan Hospital, Capital Medical University, Beijing, Beijing Municipality

Shunde Hospital of Southern Medical University, Foshan, Guangdong

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong